Results from the European Prospective Investigation into Cancer and Nutrition Link Vitamin B6 Catabolism and Lung Cancer Risk.

Auteur(s) :
Trichopoulou A., Lagiou P., Sieri S., Bueno-de-mesquita HB., Travis RC., Panico S., Boeing H., Palli D., Bergmann MM., Agudo A., Ardanaz E., Gallo V., Kaaks R., Sánchez MJ., Johansson M., Brennan P., Fortner RT., Larrañaga N., Severi G., Boutron-Ruault MC., Peeters PH., Zuo H., Ueland PM., Midttun Ø., Vollset SE., Tell GS., Theofylaktopoulou D., Fournier A., Kvaskoff M., Kotanidou A., Grankvist K., Johansson M., Garcia JRQ., Chirlaque MD., Chuang SC., Ulvik A.
Date :
Jan, 2018
Source(s) :
CANCER RESEARCH. #78:1 p302-308
Adresse :
Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. [email protected].

Sommaire de l'article
Imprimer

Circulating pyridoxal-5'-phosphate (PLP) has been linked to lung cancer risk. The PAr index, defined as the ratio 4-pyridoxic acid/(pyridoxal + PLP), reflects increased vitamin B6 catabolism during inflammation. PAr has been defined as a marker of lung cancer risk in a prospective cohort study, but analysis of a larger numbers of cases are needed to deepen the significance of this study. Here, we conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC,

Source : Pubmed
Retour